[Fluoride treatment of osteoporosis].
The development of anti-resorptive agents like vitamin D-hormones, or bisphosphonates offers a new outlook for the fluorine salt therapy. Numerous clinical studies have demonstrated increased bone mineral density in subjects treated with fluoride, however, the results of these studies were controversial. Fluoride has attracted attention as a therapeutic agent for osteoporosis because it is an effective stimulator of osteoblasts. Therefore fluoride seems to be useful, if the therapy is started in the early stages of osteoporosis, and especially in patients with intact trabecular bone. The greatest therapeutic benefit is seen with a low dose of fluoride in combination with vitamin D and calcium. This treatment will also reduce the well known side effects of fluoride. The treatment of osteoporosis could be improved with both, anti-resorptive agents and osteoblasts-stimulating agents like fluoride, but further research is needed to substantiate this therapeutical concept.
Schulz
W
W
III. Medizinischen Klinik des Klinikums Bamberg, Deutschland. ba3399@bamberg.baynet.de
D045930:Anabolic Agents / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002985:Clinical Protocols; D018849:Controlled Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005459:Fluorides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies; D013197:Stanozolol / Q000627:therapeutic use; D014807:Vitamin D / Q000493:pharmacokinetics / Q000627:therapeutic use*
D045930:Anabolic Agents; D004164:Diphosphonates; D009942:Organometallic Compounds; D014807:Vitamin D; D013197:Stanozolol; D005459:Fluorides; D002118:Calcium